Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adherence in Adolescents and Children Treated on Quetiapine

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00680888
First received: May 16, 2008
Last updated: December 7, 2010
Last verified: December 2010

May 16, 2008
December 7, 2010
August 2005
August 2008   (final data collection date for primary outcome measure)
Survival analysis of rate of adherence to treatment on quetiapine [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT00680888 on ClinicalTrials.gov Archive Site
  • Survival analysis of rate of adherence to treatment on quetiapine [ Time Frame: 12 months ]
  • Clinical and sociodemographic parameters (CGI-C, CGI-Suicidal, PANSS, HDRS, YMRS, SDQ, DAS, GAF, SUMD) possibly influencing adherence [ Time Frame: 0, 6, 12 months ]
  • Tolerability profile (UKU) possibly influencing adherence [ Time Frame: 0, 6, 12 months ]
Same as current
Not Provided
Not Provided
 
Adherence in Adolescents and Children Treated on Quetiapine
Adherence in Adolescents and Children Treated on Quetiapine

Observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive factors influencing the adherence to treatment with Quetiapine

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006

Psychosis
Not Provided
1
Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
August 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least one psychotic symptom (delusions or hallucinations) before age 18.
  • Start of treatment in a maximum period of 2 years after the onset of first psychotic symptom
  • Written informed consent by parents or guardians and patients.

Exclusion Criteria:

  • Pregnancy or lactancy
  • High risk of aggression or suicidal behaviour
  • Alcohol dependence
Both
7 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00680888
NIS-NES-SER-2006/1
No
JAVIER JIMENEZ / MEDICAL DIRECTOR, AstraZeneca Pharmaceuticals Spain S.A
AstraZeneca
Not Provided
Not Provided
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP